New Hope with this Innovative Treatment Protocol
“EVERYONE KNOWS SOMEONE WHO HAS SURVIVED CANCER, BUT UNTIL NOW NO ONE KNOWS ANYONE WHO HAS SURVIVED ALZHEIMER’S DISEASE.”
But now it is all changing!
There are some striking realities currently with Alzheimer’s disease. The population affected by it is growing rapidly; it progresses fairly quickly causing large amounts of disability and even at huge expense; the available treatments up to this point have done little to lessen symptoms and nothing to slow or stop the process.
Over the past 2-3 decades 244 drugs have been developed and studied for the treatment of Alzheimer’s. Disappointingly, 243 have failed to produce any benefit, and the one that has shown some positive result only lessens symptoms temporarily and does not alter the progressive decline seen with this disease.
This disappointment was a factor in a few researchers looking at a different approach to the disease. One of them has been Dale Bredesen, M.D. the director of the Mary Easton Alzheimer’s Research Center at UCLA and the founding president of the Buck Institute for Aging.
Extensive research has demonstrated that the primary pathology in the brain associated with its degeneration is beta amyloid. While most treatment trials had focused on ways to reduce beta amyloid, Dr. Bredesen approached his research asking “why is the brain producing this toxic protein and why is it not removing it efficiently”.
The answer proved to be that when the brain is under many different types of chemical stress it undergoes “programmed downsizing” just as a company under financial stress may downsize closing stores and laying off employees. One of the ways it does this downsizing is to increase the production of beta amyloid and slow its removal from the brain. The net effect is the loss of connections between brain cells and the eventual loss of cells themselves if the process is sustained.
Research has found that many things make small contributions to this “stress” triggering the process of downsizing. These include inflammation, nutrient deficiencies, insulin resistance, heavy metal toxicity, insufficient hormone stimulation and many more
Dr. Bredesen’s approach was to examine 36 of the known factors and treat all that were imbalanced in each patient. The result was documenting the first approach to Alzheimer’s disease to demonstrate that early phase of the disease could be stopped from progressing and actually reversed. The protocol both slows the excessive beta amyloid production, enhances it removal and helps brain cell repair.
The key point that was understood and explored in developing the Bredesen Protocol™ was that the disease does not stem from any one factor but from the co-existence of multiple factors in the same person. Similarly, an effective treatment protocol must examine a broad group of related factors in each patient and target treatment of all of them as the “sum is more than the pieces”.
The protocol involves extensive testing to identify which factors may be involved in a given patient. Once that is done, specific interventions with diet, nutritional supplements, exercise, sleep modification and indicated medical interventions such as hormone therapy are used concurrently. Practitioners using the protocol have access to a comprehensive software analysis of the collected data developed by Dr. Bredesen and his research team called “ReCode” which will guide a precise treatment process.
Beginning in 2016 Dr. Bredesen invited healthcare providers to The Buck Institute for training in The Bredesen Protocol™. These included nutritionists, family medicine and internal medicine physicians, chiropractors, psychologists, and health coaches. Dr. Banks was one of the initial providers trained and certified in this protocol in 2016.